Saudi Arabia Intravenous Solutions Market Overview, 2030

Across hospitals from Riyadh to Jeddah, hospitals first started using vein-administered sterile fluids in the mid-20th century to treat dehydration and support post-operative recovery. Early versions suffered from inconsistent formulation and contamination issues. In response, manufacturers introduced factory-prepared blends such as balanced electrolyte bags, central and peripheral nutrition, lipid emulsions, and medication-enhanced solutions manufactured in cleanrooms with rigorous filtration, heat sterilization, and aseptic filling. Physicians and clinical teams use them in public and private hospitals, emergency wards, dialysis units, oncology clinics, day-care facilities, and a growing home-infusion market. These solutions deliver hydration, salts, glucose, medicines, lipids, and nutrients directly into patients’ circulation to correct fluid loss, stabilize electrolytes, maintain blood pressure, aid post-surgery healing, and support those unable to feed orally. Over the past decade, Saudi Arabia adopted PVC-free bags, dual-chamber containers, and smart infusion pumps with dosage alerts. The nation’s Vision 2030 health investment targets, ANVISA-like SFDA regulations, and public-private infrastructure funds encouraged set-up of local fill lines. Partnerships in 2023 to build a facility producing 150 million units annually helped shift reliance from imports to domestic production. Technology transfers from global players like Baxter, Fresenius, and B. Braun enhanced aseptic protocols, while fast-track pathways from SFDA reduced delays that once held back adoption. Local R&D supported by King Abdulaziz City for Science and Technology helped optimize formulations for desert heat and chill supply chains, smoothing rollout across urban and remote healthcare facilities.

According to the research report ""Saudi Arabia Intravenous Solutions Market Overview, 2030,"" published by Bonafide Research, the Saudi Arabia Intravenous Solutions market is anticipated to grow at more than 9.17% CAGR from 2025 to 2030. Market growth stems from rising chronic illness such as diabetes, cardiovascular disease, and renal failure increased demand for high-end hospital care and wellness drips in private clinics. Expansion of medical tourism and infrastructure under Vision 2030 drove hospital upgrades and infusion therapy demand. The COVID-19 wave caused shortages in bag films and filters, but local facility build-out and SFDA’s fast-track approvals helped the market bounce back rapidly. Saudi Arabia imports raw materials polymer films and filters from Germany, the U.S., and India, while domestically filled solutions are now exported across Gulf markets. Major players such as Baxter, Fresenius, B. Braun, Pfizer, and Otsuka dominate with ready-to-use bags, smart pumps, and integrated infusion platforms. Rising local brands like Julphar Gulf Inject boosted by JV in 2017 produce under cGMP standards, with organic expansions in Ras Al–Khaimah and Saudi production hubs. Emerging entrants are building cleanroom lines but face accreditation costs and logistical challenges. Contract fill-finish providers and logistics firms support sterile packaging, cold-chain transport, and SFDA registration. Most production clusters near Riyadh, Jeddah, Dammam, and Al Jubail, while demand concentrates in major hospitals and private clinics.

The Saudi Arabia intravenous (IV) market segmented by product type mainly comprises Total Parenteral Nutrition (TPN) and Peripheral Parenteral Nutrition (PPN), both essential in supporting patients who cannot consume adequate nutrition orally or enterally. TPN dominates the market due to its critical role in providing complete, long-term nutritional support, especially for patients with severe gastrointestinal disorders, cancer, critical illness, or post-major surgeries. Delivered via central venous catheters, TPN allows administration of highly concentrated nutrient solutions tailored to meet complex metabolic needs. The growth in TPN demand is driven by increasing incidences of chronic diseases, rising geriatric population, and advancements in Saudi Arabia’s healthcare infrastructure, which emphasizes specialized patient care and nutritional support. The country’s Vision 2030 initiative, focusing on improving healthcare services and infrastructure, is further propelling the market expansion. Conversely, PPN, administered through peripheral veins, serves patients requiring short-term or partial nutritional supplementation. Although PPN has limitations regarding nutrient concentration and duration of administration, it presents fewer risks of complications like infections and is often preferred for acute care or transitional nutrition therapy. The expansion of homecare and outpatient infusion services in Saudi Arabia is increasing access to both TPN and PPN outside hospital settings, enhancing patient convenience and reducing healthcare costs. Despite challenges such as the need for specialized healthcare personnel and stringent regulatory requirements, ongoing investments in healthcare and rising awareness about clinical nutrition are fostering robust growth for both TPN and PPN segments.

The Saudi Arabia intravenous (IV) nutrition market segmented by composition encompasses a variety of critical nutrients formulated to address diverse clinical requirements. Carbohydrates, mainly delivered as dextrose solutions, serve as the primary energy source in parenteral nutrition, supporting patients’ metabolic demands especially during recovery from surgery, trauma, or illness. The increasing number of surgical procedures and critical care cases in Saudi Arabia bolsters carbohydrate utilization. Vitamins and minerals play a vital role in maintaining immune function, metabolism, and preventing micronutrient deficiencies, typically included as standardized vitamin and trace element complexes in IV formulations consistent with clinical nutrition guidelines. The growing awareness of malnutrition’s impact on patient outcomes, especially among oncology and elderly populations, is increasing demand for single dose amino acids, essential for protein synthesis and tissue repair. Parenteral lipid emulsions provide essential fatty acids and high-calorie density; the market is witnessing gradual adoption of advanced multi-source lipid emulsions combining soybean, olive, and fish oils, which offer improved safety and reduced inflammatory effects aligning with global clinical nutrition trends. The others segment includes electrolytes, buffers, antioxidants, and condition-specific additives such as glutamine, enabling tailored IV nutrition regimens suited to individual patient needs. Saudi Arabia’s strong investment in healthcare modernization, expanding hospital nutrition programs, and emerging home infusion services facilitate access to these advanced nutritional compositions. Additionally, regulatory frameworks ensuring product safety and efficacy support market growth.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Intravenous Solutions Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Total Parenteral Nutrition
• Peripheral Parenteral Nutrition

By Composition
• Carbohydrates
• Vitamins and Minerals
• Single Dose Amino Acids
• Parenteral Lipid Emulsion
• Others Show more